ここらへんをRON氏の定義のリバウンドをあてはめて読むとわからなくなるのです。 Suplatast tosilate It has been suggested that a rebound phenomenon occurs in people with atopic eczema who have been treated for prolonged periods with strong topical corticosteroids. We found one small RCT328 that evaluated the role of an anti-allergic medication called suplatast tosilate (which down-regulates production of IgE and related cytokines) versus bufexamace ointment to prevent rebound from topical steroids in atopic eczema.
Benefits Thirty-two patients who had been treated with strong steroid ointment for several years were randomised to either bufexamace ointment (a non-steroidal antiinflammatory ointment) or bufexamace ointment and oral suplatast tosilate (400 mg/day). In the control group, 15 patients experienced the rebound phenomenon after 2 weeks compared with only two of 17 patients in the active group (rebound was undefined). Several cytokines increased in the control group but not in the active group.
Harms No adverse effects were reported in this small study.
Comment The issue of rebound from regular use of topical steroids is a serious and important one as it is possible that the regular use of corticosteroids increases the chronicity of disease while benefiting the short-term control of flare-ups. This small study was unblinded (the control group did not have an oral placebo) and the ‘rebound’ was completely undefined and therefore highly prone to investigator bias. The study should be followed by a randomised, controlled double-blind trial over a long period with clinical outcomes and a vehicle-only comparison group.
前にもあなたのいる前ではっきり書いたはずですが、世間での定義(=私が引用している定義であり Hoare et al. のレビューに載っている定義でもある)は、"the regular use of corticosteroids increases the chronicity of disease" も除外していないので、何も矛盾してないですよ。
その論文 H. Kimata, Ann Allergy 1999;82(3):293? の、該当する文章の現物は こうなってます。
Methods This is a randomized, placebo controlled study. Patients with atopic dermatitis who had been treated with strong steroid ointment (dexamethasone valerate) for several years were divided into two groups. One group (the control group, n = 15) was treated with a non-steroid anti-inflammatory ointment (bufexamac ointment), while the other group (the suplatast tosilate group, n = 17) was treated with the anti-allergic medications, suplatast tosilate and bufexamac ointment. In each group, in vitro production of immunoglobulins and cytokines before and after 2 weeks of treatment was measured.